Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vilaprisan in symptomatic endometriosis
NCT03573336Phase 2Terminated
- Sponsor
- Bayer
- Start
- Jul 2018
- Primary completion
- Mar 2019
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of vilaprisan in endometriosis (3 arms), sponsored by Bayer. Primary endpoint: Mean Worst Pelvic Pain (Measured on a Numerical Rating Scale [NRS], Recorded in the Daily Endometriosis Symptom Diary [ESD]). Started Jul 2018; status: terminated.
02
Drugs
vilaprisan
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT03573336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573336.